W. Eiermann
Impact in
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.02%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Papers in
- Oncology 106
- HER2/EGFR in Cancer Research 46
- Cancer Treatment and Pharmacology 42
- PARP inhibition in cancer therapy 15
- Cancer Research 100
- Breast Cancer Treatment Studies 90
- Co-authors
- José Baselga (9 shared papers)Janet Wolter (4 shared papers)Dennis J. Slamon (12 shared papers)Mark D. Pegram (9 shared papers)Larry Norton (1 shared paper)Thomas Fleming (1 shared paper)Brian Leyland‐Jones (1 shared paper)Virginia Paton (1 shared paper)
- Journals
- Journal of Clinical Oncology (54 papers)Cancer Research (21 papers)Annals of Oncology (18 papers)European Journal of Cancer (11 papers)Cancer (5 papers)
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
W. Eiermann
217 papers receiving 24.1k citations
W. Eiermann's Hit Papers
Peers
Comparison fields: 5 of 148
- Cancer Research 8.4k
- Oncology 13.2k
- Radiology, Nuclear Medicine and Imaging 4.4k
- Pulmonary and Respiratory Medicine 3.7k
- Genetics 2.8k
Countries citing papers authored by W. Eiermann
This map shows the geographic impact of W. Eiermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Eiermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Eiermann more than expected).
Fields of papers citing papers by W. Eiermann
This network shows the impact of papers produced by W. Eiermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Eiermann. The network helps show where W. Eiermann may publish in the future.
Co-authors
The 25 scholars most cited alongside W. Eiermann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 233 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Hit paper breakdown → | 2001 | 8935 |
| 2 | Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes Hit paper breakdown → | 2012 | 1905 |
| 3 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation Hit paper breakdown → | 2018 | 1470 |
| 4 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2010 | 923 |
| 5 | Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update Hit paper breakdown → | 2006 | 570 |
| 6 | Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study Hit paper breakdown → | 2001 | 562 |
| 7 | 2008 | 468 | |
| 8 | 2005 | 408 | |
| 9 | 1989 | 380 | |
| 10 | 2011 | 368 | |
| 11 | Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort Hit paper breakdown → | 2014 | 364 |
| 12 | 2011 | 355 | |
| 13 | Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. | 1998 | 355 |
| 14 | 1996 | 322 | |
| 15 | 2017 | 305 | |
| 16 | 2007 | 303 | |
| 17 | 2013 | 274 | |
| 18 | 2003 | 273 | |
| 19 | 2020 | 273 | |
| 20 | 2002 | 232 |
About W. Eiermann
W. Eiermann is a scholar working on Oncology, Cancer Research, Genetics, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 233 papers that have together received 25.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (90 papers), HER2/EGFR in Cancer Research (46 papers), Cancer Treatment and Pharmacology (42 papers), Advanced Breast Cancer Therapies (30 papers), Estrogen and related hormone effects (28 papers), BRCA gene mutations in cancer (15 papers), PARP inhibition in cancer therapy (15 papers) and Breast Lesions and Carcinomas (14 papers). The work is most often cited by research in Cancer Research (8.4k citations), Oncology (13.2k citations), Radiology, Nuclear Medicine and Imaging (4.4k citations), Pulmonary and Respiratory Medicine (3.7k citations) and Genetics (2.8k citations). W. Eiermann has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include José Baselga, Janet Wolter, Dennis J. Slamon, Mark D. Pegram, Larry Norton, Thomas Fleming, Brian Leyland‐Jones, Virginia Paton, Alex Bajamonde and Steven Shak. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, European Journal of Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.